RedHill Biopharma

RedHill Biopharma Ltd. develops medicines for gastrointestinal and infectious diseases. It operates through Commercial Operations, and the Research and Development segments. The Commercial Operations segment covers all areas relating to the commercial sales and is being performed by the subsidiary in the U.S. The Research and Development segment includes the study and licensing of therapeutic candidates. Its products include Talicia, Movantik, and Aemcolo. The company was founded by Dror Ben-Asher and Ori Shilo on August 3, 2009 and is headquartered in Tel Aviv, Israel.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

TEL-AVIV, Israel and RALEIGH, N.C., Oct.  28, 2019  (GLOBE NEWSWIRE) --  RedHill Biopharma Ltd.  (Nasdaq:  RDHL ) (Tel-Aviv Stock Exchange:  RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, proprietary drugs for the treatment of gastrointestinal diseases, today announced that two oral presentations and two posters on two of the Company’s leading drug candidates, RHB-1051 (Talicia®, H. pylori infection) and RHB-104 (Crohn’s disease) will be presented at the American College of Gastroenterology (ACG) 2019 Annual Scientific Meeting, being held October 25-30, in San Antonio, Texas. In addition to the four presentations at ACG, RedHill will be sponsoring an H. pylori Disease State educational presentation in the Exhibitor Theater and will have a booth (#426) located in the Exhibit Hall.

RedHill Biopharma to Present New Phase 3 Data on RHB-105 and RHB-104 at the American College of Gastroenterology 2019 Annual Meeting

TEL-AVIV, Israel and RALEIGH, N.C., Oct.  18, 2019  (GLOBE NEWSWIRE) --  RedHill Biopharma Ltd.  (Nasdaq:  RDHL ) (Tel-Aviv Stock Exchange:  RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, proprietary drugs for the treatment of gastrointestinal diseases, today announced that it has entered into a strategic collaboration with Cosmo Pharmaceuticals N.V. (SIX: COPN) (“Cosmo”).

RedHill Biopharma Announces $36 Million Strategic Investment by Cosmo Pharmaceuticals and U.S. Rights to Approved Travelers’ Diarrhea Drug AEMCOLO

TEL-AVIV, Israel and RALEIGH, N.C., Oct.  16, 2019  (GLOBE NEWSWIRE) --  RedHill Biopharma Ltd.  (Nasdaq:  RDHL ) (Tel-Aviv Stock Exchange:  RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, proprietary drugs for the treatment of gastrointestinal diseases, today announced its support of a number of prevention and awareness initiatives for Stomach Cancer Awareness Month, including its sponsorship of the No Stomach For Cancer’s (NSFC) Spotlight on Stomach Cancer Symposium. The symposium will take place on Saturday, October 26, 2019, from 8 a.m. - 2 p.m. MST at the University of Arizona in Tucson, Arizona.

RedHill Biopharma Sponsors No Stomach For Cancer’s Symposium Ahead of Stomach Cancer Awareness Month

TEL-AVIV, Israel and RALEIGH, N.C., Oct.  11, 2019  (GLOBE NEWSWIRE) --  RedHill Biopharma Ltd.  (Nasdaq:  RDHL ) (Tel-Aviv Stock Exchange:  RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, proprietary drugs for the treatment of gastrointestinal diseases, today announced  full Week 52 results for all subjects in the previously announced positive Phase 3 randomized, controlled study of RHB-104 in Crohn’s disease (the “MAP US study”) and supportive top-line results from the open-label extension Phase 3 study (the “MAP US2 study”).

RedHill Biopharma Announces Full Results from Positive MAP US Phase 3 Study and Supportive Top-Line Results from MAP US2 Open-Label Extension Study with RHB-104 in Crohn’s Disease

TEL-AVIV, Israel and RALEIGH, N.C., Aug.  27, 2019  (GLOBE NEWSWIRE) --  RedHill Biopharma Ltd.  (Nasdaq: RDHL) (Tel-Aviv Stock Exchange:  RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, proprietary drugs for the treatment of gastrointestinal diseases, today announced that the Company will present a corporate overview at two investor conferences in September:

RedHill Biopharma to Present at Upcoming Investor Conferences in September

TEL-AVIV, Israel and RALEIGH, N.C., Aug.  21, 2019  (GLOBE NEWSWIRE) --  RedHill Biopharma Ltd.  (Nasdaq:  RDHL ) (Tel-Aviv Stock Exchange:  RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, proprietary drugs for the treatment of gastrointestinal diseases, today announced that it will present data from the positive Phase 3 clinical studies of RHB-105 (Talicia®)1 for H. pylori infection and RHB-104 for Crohn’s disease at the upcoming American College of Gastroenterology (ACG) 2019 Annual Scientific Meeting (October 25-30, 2019). In addition, an oral presentation on RHB-105 (Talicia) was also accepted for presentation at the XXXIInd International Workshop on Helicobacter & Microbiota in Inflammation and Cancer of the European Helicobacter and Microbiota Study Group (EHMSG 2019) (September 5-7, 2019).

RedHill Biopharma Announces Acceptance of Oral Presentations on RHB-105 (H. pylori) and RHB-104 (Crohn’s Disease) Phase 3 Data at ACG 2019 Annual Scientific Meeting

The multi-year laborious clinical trials to demonstrate therapeutic efficacy for Talicia in H. pylori eradication were validated with positive clinical outcomes in two Phase 3 trials.

RedHill And Talicia In H. Pylori: The PDUFA Countdown

RedHill Biopharma Ltd. (RDHL) CEO Dror Ben-Asher on Q2 2019 Results - Earnings Call Transcript

Apellis Pharma

Dynavax Technologies

Here's what you need to know about the upgrades and bullish price targets analysts recently slapped on these drugmakers.

3 Biotech Stocks That Could Double Your Money.

In Q4/2018, RedHill Biopharma announced that the Phase 3 confirmatory trial for Talicia in the eradication of H. pylori infection was successful.

RedHill Biopharma And Talicia: The NDA

RedHill Biopharma Ltd. (RDHL) CEO Dror Ben-Asher on Q1 2019 Results - Earnings Call Transcript

Talicia by RedHill is a novel proprietary fixed-dose triple therapy combination of two antibiotics (amoxicillin/rifabutin) and a proton pump inhibitor (PPI; omeprazole) in an all-in-one oral capsule.

RedHill And Talicia In Helicobacter Pylori Eradication And The Market Assessment

News for RedHill Biopharma Stock (RDHL)